Processa (PCSA) Director Baluch Khoso Receives 33,500 RSUs

What Happened Baluch Khoso, a director of Processa Pharmaceuticals, was granted 33,500 restricted stock units (RSUs) on July 26, 2026. The award shows an acquisition price of $0.00 (no cash paid); the RSUs are reported as derivative securities. Per the filing, the RSUs vested upon grant but will not be distributed immediately.

Key Details

• Transaction date: 2026-07-26; Form 4 filed: 2026-07-28.
• Security/amount: 33,500 RSUs granted; acquisition price reported $0.00 (derivative award).
• Shares owned after transaction: not specified in the summary information provided in this request.
• Footnote F1: Each RSU = contingent right to one share. Although vested, distribution is deferred until the earlier of: (i) termination; (ii) six-month anniversary of grant; (iii) change of control; or (iv) death.
• Footnote F3: Share counts reflect the 1-for-25 reverse stock split effective Dec 17, 2025.
• Footnote F2 appears in the filing (standard option vesting language) but does not apply to this RSU grant.
• Timeliness: Filed two days after the transaction date (no late-filing indication in the provided data).

Context This was a compensatory equity award (RSUs), not an open-market purchase or sale. RSU awards are common executive/director compensation and do not by themselves indicate buying or selling sentiment; value will be realized when/if the RSUs are settled into shares under the stated distribution conditions.